Objective. Despite the high prevalence of chronic multisite pain, there is little consensus on methods to characterize it. Commonly used assessments report only one dimension of pain, that is, intensity, thus ignoring the spatial aspect of pain. We developed a novel pain quantification index, the Integrated Pain Quantification Index (IPQI), on a scale of 0 to 1 that integrates multiple distinct pain measures into a single value, thus representing multidimensional pain information with a single value.
Introduction
Chronic pain is a highly pervasive worldwide complaint, with a World Health Organization study reporting an overall prevalence of 20% in primary care facilities [1] . Pain in multiple areas is common, with an estimated 53.1% to 88% of patients reporting multiple painful areas, or multisite pain [2] [3] [4] [5] [6] [7] . Multisite pain is also associated with greater disability, worse physical function, greater psychological distress, and lower quality of life than single-site pain [2] [3] [4] 6, 8] . Despite its higher prevalence and greater impact than single-site pain, little to no consensus exists regarding standardized assessments for characterizing multisite pain. The lack of standardized assessments makes comparison between studies difficult and is problematic for furthering our understanding of chronic multisite pain's population, treatment, and effects on quality of life.
Currently available methods are either too simplistic or were not originally developed for characterizing multisite pain. Each patient has a different number of noncontiguous painful areas, each site with different sizes, and potentially differing levels of pain intensities and persistence (e.g., intermittent or constant). Despite this complexity, two of the most commonly used pain assessments-the visual analog scale (VAS) and the numeric rating scale (NRS)-collect and report only one pain measure (intensity). Pain drawings collect data on spatial extent of pain, but are also reported using single variables, like the number of noncontiguous painful areas or percent area in pain [2, [4] [5] [6] 9, 10] . These methods are widely accepted for their simplicity and are valuable in clinical settings for assessing before-and aftertreatment effects. However, each individual pain measure is only partially informative on its own, and insufficient for comprehensively characterizing multisite pain.
Several definitions have been used for characterizing multisite pain, with little to no consensus between the definitions. These include the American College of Rheumatology's (ACR's) definition [11] [12] [13] [14] or the Manchester definition on chronic widespread pain (CWP) [15] . These definitions were originally developed as investigational tools in fibromyalgia patients, but have since been used to characterize other chronic pain populations, such as musculoskeletal pain patients. Per these definitions, pain is considered widespread only if specific body regions are afflicted [12] [13] [14] [15] . For example, per the ACR definition, CWP is defined as pain present in at least two contralateral body quadrants and the axial skeleton. Multisite pain, though, can occur without satisfying the criteria set by these definitions [11, 16] . Further, chronic pain can evolve over time, with changing severity and spatial distribution, with transition between localized and widespread areas, rendering such definitions not useful for longitudinal comparisons in the overall chronic pain population. Thus, though such definitions may be valuable for diagnostic evaluations, they may be of limited use for reporting chronic pain. An alternative approach may be to allow for collecting and reporting pain data across several dimensions of multisite pain, such as spatial distribution, intensity, and persistence.
The objective of this study was to develop an index that combined information from several pain measures into a single value. To this end, we developed an Integrated Pain Quantification Index (IPQI) that integrates information on spatial distribution, intensity, and persistence measures into one final value. Spatial distribution is quantified using the number of noncontiguous painful areas, dermatome distance, and percent body in pain. Pain persistence and intensity data are collected and integrated over several painful areas, as each area may have differing levels of both measures. Our novel index was developed and tested in chronic pain patients from the Multiple Areas of Pain (MAP), which included patients with NRS >5 and at least six months' pain history. We also collected data on quality of life and psychological well-being using well-established assessments spanning all domains recommended by the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT). We validated and characterized IPQI using these assessments.
Methods

Subjects
Eight-hundred twenty-eight subjects from 14 centers in the United States enrolled in this single-visit, noninterventional, epidemiological study. All 14 centers received institutional review board approval before enrolling the subjects. Screening, informed consent, and data collection of all study assessments were performed in a single visit. Table 1 shows the inclusion and exclusion criteria for this study. Subjects were included if they were older than 18 years of age with chronic pain of the trunk and/or limbs for at least six months and an average overall pain intensity of at least 5 on the NRS scale. Subjects were not included if they had undergone an interventional pain procedure within the one month prior to the study or were implanted with an active medical device for treating pain or exhibited characteristics that rendered them ineligible for current or future pain treatment with spinal cord stimulation systems, which are often used for treating multisite pain.
Data Collection and Study Assessments
Data on pain and quality of life were collected using a variety of paper questionnaires. Pain data included a pain drawing, the Regional Pain Rating (RPR) questionnaire, the NRS, and the Short Form McGill Pain Questionnaire version 2 (SF-MPQ-2). Quality of life assessments were collected using the EuroQol-5D (EQ-5D-5L), the Oswestry Disability Index version 2.1a (ODI), Pain Disability Index [17] , the seven-item Generalized Anxiety Disorder Scale (GAD-7), the Center for Epidemiologic Studies Depression Scale (CES-D), and the Work Productivity and Activity Impairment Questionnaire: Specific Health Problems version 2.0 (WPAI: SHP).
The IPQI was constructed using data from the pain drawing and the RPR questionnaire. Figure 1 displays the body diagrams from both of the pain assessments. The pain drawing is a full anterior and posterior body diagram where subjects were asked to shade in all areas they had experienced pain in over the past seven days. The RPR form is a full anterior and posterior body diagram that has been segmented into 47 anatomical regions to facilitate pain rating data collection. For each of the 47 regions, subjects were instructed to rate their average pain intensity, peak pain intensity, and pain persistence over the last seven days using a numeric scale of 0-3. Average intensity and peak intensity were delineated as 0 ¼ "no pain," 1 ¼ "mild pain," 2 ¼ "moderate pain," and 3 ¼ "severe pain." For pain persistence, 0 ¼ "never hurts," 1 ¼ "rarely hurts," 2 ¼ "frequently hurts," and 3 ¼ "always hurts."
The NRS and SF-MPQ-2 were scored to assess pain intensity and quality, respectively, across the entire body. The SF-MPQ-2 questionnaire comprises a set of descriptive questions to assess four components of pain: continuous pain, intermittent pain, neuropathic pain, and affective descriptors. These subscales can be further combined to form an overall SF-MPQ-2 score. Intensity ratings for both measures range from 0 to 10, where 0 corresponded to "none" and 10 corresponded to "worst imaginable." These pain measures, along with the quality of life assessments, were used to assess the validity of the IPQI.
Statistical Analysis
Pain drawings were scanned and pixelated to allow computerized analysis. Each pixel represented a point on the body and was assigned a value of 0 or 1 depending on the absence or presence of pain, respectively. The number of distinct, noncontiguous painful areas was determined by iteratively comparing the presence of pain across neighboring pixels, grouping together pixels that belonged to a contiguous pain area. The size of a painful area relative to the entire body was determined by the proportion of pixels belonging to the painful area. Considering that only spinal cord stimulator (SCS)-eligible subjects were included in this study, and that SCS is indicated for treatment of pain below the head, analyses were performed only on body areas below the head.
A standardized dermatome map (source: Atlas of Human Anatomy by Frank Netter) was overlaid on top of the pain drawing to identify the dermatomes associated with each painful area. Because the distance between painful areas can affect choice of treatment, our intended use of the dermatome map was to introduce a single dimensional spatial measure for the twodimensional body diagram. We defined the dermatome distance as number of vertebrae between the anteriorand posterior-most spinal nerves associated with innervating the painful dermatomes. This metric can be interpreted as the maximum distance between painful areas, so not all dermatomes between the painful areas need to be affected. For example, a subject with painful areas in C2 and S5 will have the same dermatome distance as a subject with full body pain, where every dermatome between C2 and S5 is affected. There is a total of 29 dermatomes, supplied by seven cervical nerves (C2 to C8), 12 thoracic nerves (T1 to T12), five lumbar nerves (L1 to L5), and five sacral nerves (S1 to S5). The Table 1 Inclusion and exclusion criteria Inclusion Criteria • 18 years of age or older when written informed consent is obtained • Chronic pain of the trunk and/or limbs lasting for at least 6 mo • Overall pain intensity of at least 5 on a 0-10 numeric rating scale • Able to independently complete all assessments in English • Signs an institutional review board-approved informed consent form provided in English Exclusion Criteria • Currently implanted with an active implantable medical device to treat pain (e.g., spinal cord stimulator, peripheral nerve stimulator, motor cortex stimulator, implantable drug pump) • Currently exhibits any characteristic that renders the subject ineligible for current or future treatment with SCS for chronic pain of the trunk and/or limbs (e.g., inappropriate primary pain diagnosis, possible nonphysiological exam, presents with at least 2 Waddell's signs) • Has undergone an interventional pain procedure less than 1 mo prior to study assessments (e.g., epidural steroid injection, selective nerve block, sympathetic block, radiofrequency procedures, SCS trial lead removal)
dermatome distance variable can take on values between 0 and 28.
Similarly, the RPR questionnaire was overlaid on top of the pain drawing so that pain intensity and pain persistence ratings could be obtained for each painful area. When a painful area was distributed over more than one body region from the RPR diagram, we used the rating for the body region that encompassed the largest proportion of the painful area. We created the size-scaled RPR (ssRPR) variable to summarize the multiple pain ratings across different painful areas. Each rating was first scaled by the percentage of the body covered by the painful area, so that ratings on larger painful areas were given more weight than ratings on smaller painful areas. The size-adjusted ratings were then summed across all painful areas to create a standardized overall measure for average pain intensity, peak pain intensity, and pain persistence. We averaged these standardized measures to create the ssRPR, a variable that quantified the RPR ratings in a consistent manner across all subjects with multiple areas of pain. The ssRPR variable can take on values between 0 and 300, where 0 represents no pain and 300 represents severe, always present pain across 100% of the body.
The IPQI was developed by combining the pain variables of number of noncontiguous painful areas, dermatome distance, and ssRPR into one score. ssRPR provides information about the size of the painful areas, pain severity, and pain persistence. Each pain variable was first standardized by subtracting its mean and dividing by its standard deviation. We performed a principal component analysis (PCA) on the three pain variables and used the first principal component as a summary score. The summary score was calculated for the ith subject as
where x a , x d , and x s are PCA loadings and can be interpreted as weights. The first principal component for each patient was then log-transformed to make the index more sensitive to changes in the lower end of the pain measures' spectra. Higher resolution at the lower end of the spectrum was desirable because, as shown by previous epidemiological studies as well as this study, most patients fall in the lower end of pain spectrum measurements. The log-transformed first principal component was then scaled to a [0, 1] interval for interpretability and ease of use. To assess the generalizability of the IPQI, we performed a 10-fold cross-validation of the method in which we randomly split the data into 10 sets successively, train on nine of the sets and test on one set, making it such that all patients have been in both the training and test set. For each of the folds, the IPQI formula derived from the training set was used to predict IPQI values for the test set. These predictions were then compared with values obtained by the IPQI formula derived from the test set only. The generalizability of the method to independent data was assessed by calculating the prediction error across all crossvalidation folds.
Statistical analyses were performed using R software. We calculated Pearson's pairwise correlations between various pain measures and the IPQI, NRS, and SF-MPQ-2, using Fisher Z transformation to calculate 95% confidence intervals (CIs).
Results
Among 828 enrolled subjects, 810 (97.8%) completed the pain drawing assessments during the single visit. The remaining subjects included 15 who withdrew from the study and 3 who did not complete the pain drawing. 
Pain Drawing and Regional Pain Rating Questionnaire
Given the large study cohort, pain drawings depicted a wide variety of pain patterns. Figure 2 displays the histograms and summary statistics for total percent body area in pain, number of noncontiguous painful areas, and the maximal anterior-posterior dermatome distance affected by pain.
Our study population had subjects with limited, localized pain as well as those with widely distributed, almost fullbody pain. Total percent body area in pain ranged from 0.2% to 98.1%, with the 25th and 75th percentiles at 4.8% and 21.5%, respectively. The majority of the subjects (52.8%) had pain in over 10% of the body. We also observed a wide range of values for the number of noncontiguous painful areas. These ranged from 1 to 43, with 25th and 75th percentiles at 2 and 8, respectively; 88.3% (N ¼ 715) of subjects reported more than one painful area. We used pain drawing data to calculate a novel distance metric to quantify the maximum distance between painful areas. A majority of our subjects experienced painful areas that were far apart in terms of dermatome location, with 61.1% (N ¼ 495) of subjects experiencing pain in dermatomes associated with the cervical spine as well as the lumbar and/or sacral spine. The dermatome distance ranged from 2 to 28 dermatomes, with 25th and 75th percentiles at 10 and 25 dermatomes, respectively.
The majority of the subjects' in our study experienced different levels of pain intensity and pain persistence across the different painful areas. Among subjects with more than one area of pain, percentage of subjects who gave different ratings across painful areas was 80.6% for average pain intensity, 81.3% for peak pain intensity, and 78.7% for pain persistence. This suggests that limiting multisite pain patients to a single intensity or persistence score, such as the NRS or VAS, may result in incomplete data. RPR data overcome this limitation by collecting intensity and persistence data over all the painful areas. We weighted RPR ratings by percent area in pain to develop the ssRPR. Out of a possible range of 0-300 on the ssRPR (see the Methods), patients in this study cohort had a range of 0-279, with mean at 27.6 (SD ¼ 41.87).
As expected, similar pain measures had strong correlations with each other. For example, ssRPR was derived from, and strongly correlated with, percent body area in pain (Pearson's R ¼ 0.97). Also, as expected, distinct pain measures had weak correlations with each other. For example, number of noncontiguous painful areas had a negligible correlation with percent body area in pain (R ¼ 0.12; 95% CI ¼ 0.05-0.19) and ssRPR (R ¼ 0.08; 95% CI ¼ 0.01-0.15). These results support our initial hypothesis that individual pain measures may not be sufficient to characterize the distinct aspects of pain. These results also had implications on deciding pain measures to be used for IPQI development. To avoid repetition of information in IPQI development, we combined only the distinct pain measures and not similar pain measures.
Integrated Pain Quantification Index
Details of IPQI development are described in the Methods section. Briefly, IPQI is based on a mathematical procedure for combining several pain measures into one. The IPQI was constructed using the number of noncontiguous painful areas, dermatome distance, and size-scaled RPR, representing distinct measures of spatial pain distribution, severity, and persistence into one index. Pain measures similar to each other were not used for IPQI development to avoid redundancy of data. Specifically, as ssRPR is derived from percent area in pain, we only used ssRPR, which provides additional information about pain intensity and persistence. IPQI is bound by minimum and maximum values of 0 and 1, respectively, with 0 representing no pain and 1 representing continuous, severe pain in the full body.
Principal component analysis was performed (see the Methods) to reduce the dimensionality of the pain variables. The first, second, and third principal components explained 56.3%, 30.6%, and 13.1% of the variation among the pain variables, respectively. The first principal component was used to summarize the data, and its loadings were w a ¼ 0.530 for number of noncontiguous painful areas, w d ¼ 0.684 for dermatome distance, and w s ¼ 0.500 for ssRPR. The loadings suggest that all three variables contributed to the summary score, with dermatome distance being the most influential variable, followed by number of noncontiguous painful areas, then ssRPR. IPQI scaled from 0 to 1, with 0 representing no pain and 1 representing continuously present, full-body pain of extreme intensity. Cross-validation of our method resulted in a mean squared error of 0.048, suggesting generalizability of the IPQI metric. Figure 3 shows the distribution of the IPQI for the study population, along with sample pain drawings colorcoded by average pain intensity. The IPQI values ranged between 0.14 and 0.78, with the mean at 0.52 (SD ¼ 0.13) and median at 0.55. Overall, subjects with high IPQI typically had many, widely distributed painful areas of high severity and persistence. In comparison, subjects with low IPQI typically had localized pain.
To establish a guideline for the interpretation of IPQI values, we categorized the subjects into groups by stepwise increases of 0.1 in IPQI. Figure 4 shows scatter plots color-coded by IPQI group and illustrates the pairwise relationships between pain measures used to construct IPQI, that is, the number of noncontiguous painful areas, dermatome distance, and ssRPR. Higher values of IPQI were typically associated with higher values for all of the pain measures. Table 5 shows the mean (SD) values for pain measures in subjects belonging to IPQI groups (0 ! value 0.3; 0.3 > value 0.6; and 0.6 > value 1). In particular, subjects with an IPQI 0.3 had a small number of noncontiguous painful areas across several adjacent dermatomes. The ssRPR scores for this group were low, suggesting that the painful areas were small. On the other end of the spectrum, subjects with an IPQI > 0.6 had widely distributed painful areas with a dermatome distance of at least 20. Some of these subjects had a large number of noncontiguous painful areas, while others had fewer but high ssRPR, suggesting that the noncontiguous painful areas, though small in number, covered large areas and/or had high pain intensity and persistence ratings ( Figure 4B ).
Based on these observations, we provide the following guideline for the interpretation of the IPQI values. Subjects with IPQI scores of 0 ! value 0.3, 0.3 > value 0.6, and 0.6 > value 1 were considered to have "limited," "moderate," and "multidimensional, complex" pain, respectively. Per this categorization, 7% (N ¼ 57) of subjects had limited pain, 61.4% (N ¼ 497) of subjects had moderate pain, and 31.5% (N ¼ 255) of subjects had complex pain.
Subject-Rated Standardized Assessments
Pearson's pairwise correlations between various pain measures and IPQI, NRS, and SF-MPQ-2 are shown in Table 4 .
IPQI had strong correlations with all pain measures (Pearson's R range ¼ 0.57-0.93), demonstrating its value in accurately summarizing and representing several pain measures. Furthermore, as compared with NRS or SF-MPQ-2, IPQI had the strongest correlations with all pain measures. The SF-MPQ-2, which is a composite score that focused on pain quality, had moderate correlations with the pain measures (Pearson's R range ¼ 0.26-0.35). NRS, which focuses on overall pain intensity, had the weakest correlations with pain measures, which is not surprising given that pain intensity and spatial distribution are distinct pain concepts (Pearson's R range ¼ 0.03-0.20). Correlations between the NRS and scaled pain intensity ratings were stronger compared with correlations with spatial pain variables but still weak, as the NRS was a single-response questionnaire and the scaled intensity ratings were created by combining pain intensity ratings across all painful areas.
We also collected data on a number of secondary, wellestablished clinical assessments spanning across domains recommended by IMMPACT. Secondary assessments of pain disability, overall mental well-being, and work productivity were not used in the development of the IPQI, and they provide an independent validation of our newly developed index. Specifically, we were Quantitative Index Multiple Areas of Pain interested in testing for associations between these assessments and the IPQI. Table 5 shows the mean (SD) values for each clinical assessment in subjects belonging to IPQI groups (0 ! value 0.3; 0.3 > value 0.6; and 0.6 > value 1). Overall, subjects with a high IPQI had increased levels of depression, anxiety, and disability, and reduced productivity and quality of life compared with subjects with a low IPQI. Some assessments were more sensitive to IPQI changes than others. SF-MPQ-2, ODI, GAD-7, and CES-D were sensitive to changes in IPQI, whereas the self-care component of the EQ-5D-5L was not sensitive to IPQI changes. All associations were significant (P < 0.0001).
Discussion
The IPQI is the first scale to integrate anatomy-, time-, and intensity-related pain measures into a single metric to quantify chronic multisite pain. The development of IPQI, therefore, allows for multiple pain dimensions in all chronic pain subjects to be compared on one scale for the first time. The IPQI was constructed using a large chronic pain patient population and has implications for the design of future clinical investigations given that most subjects have more than one painful site [2, 6, 14, 16] .
Weak to moderate correlations between different pain measures illustrate that reporting one pain variable may not be sufficient to characterize the multidimensional nature of pain. The IPQI had a strong positive correlation with each pain measure used to construct it, and can therefore be used as single score to represent complex multidimensional pain information. Further, compared with the standardized pain assessments of the NRS and SF-MPQ-2, the IPQI had the strongest correlations with the different pain measures, suggesting that our newly developed index may provide a more accurate representation of chronic pain than currently used standardized assessments.
While more intense pain or more extensive distribution are typically associated with increased levels of psychological distress, disability, and reduced levels of quality of life and work productivity [4, 6, 8, 15] , linear regressive correlations show no to modest predictive value between these measures [8, 18, 19] . The IPQI construct was validated by modest, yet positive associations with multiple domains of functional impairment. Increasing IPQI scores were generally positively associated with increased disability and psychological distress, and negatively associated with quality of life and work productivity, suggesting its relevance for factors impacted by pain. Some assessments were more sensitive to changes in IPQI than others. Increasing IPQI was associated with relatively large changes in SF-MPQ-2, ODI, GAD, CES-D, and work productivity scores, but relatively small changes on the NRS scale. The different sensitivities could be due to differences in the expanse of data collected by each assessment. For example, the NRS is collected and reported as one number, whereas other scores are derived using several data points, allowing for increased saliency. The relative lack of sensitivity of VAS or NRS scores supports previous criticisms that these may not be appropriate for quantifying chronic pain.
In our study, the vast majority of subjects suffered from multiple widely dispersed painful areas, with differing pain intensity and persistence in each area. Use of the NRS or VAS, which provide a global estimate of only one pain dimension (pain intensity), is therefore not appropriate for capturing the multidimensional nature of chronic pain. Such limitations may explain why longitudinal clinical studies using VAS or NRS scores often register only small differences in treatment effectiveness. Quantitative measures such as size or number of noncontiguous painful areas provide alternatives to characterize chronic pain, but are not feasible for comparison purposes. The IPQI overcomes such limitations by combining several pain variables, and may be useful in quantifying pain and treatment effectiveness in longitudinal clinical studies.
Pain variables used in the construction of the IPQI attempt to bypass the drawbacks of some traditional assessment scores. For instance, though pain drawings provide information on the number of noncontiguous painful areas, there is no consensus on where different anatomical "sites" should be delineated, with boundaries in traditional assessments being arbitrary and lacking a physiological basis. The IPQI circumvents this limitation by accounting for the number of noncontiguous painful areas instead. Additionally, the ssRPR combines anatomical extent, persistence, and intensity, whereas pain drawings alone only give information on anatomical extent. The IPQI also accounts for distance between painful areas, for which there is currently no metric. This variable has implications for the treatment of chronic multisite pain, as it is more difficult to simultaneously treat pain in areas that are far apart than it is to treat pain in neighboring areas. To address this, we measured the distance between vertebral levels of painful dermatomes. Knowledge of this distance may help guide treatments where accurate anatomical targeting is important. For example, spinal cord stimulation treatment is greatly dependent on knowledge of the distance between painful areas.
Despite the benefits of the IPQI, its nascence means that there will be limitations. For one, drawings on anterior and posterior diagrams may indicate a single, contiguous painful area but be interpreted as two painful areas, potentially overestimating the number of noncontiguous painful areas. Estimation of painful areas may also be affected by the requirement of scanning drawings, which are then pixelated. Furthermore, while the IPQI integrates several different variables into a single value, it only accounts for values that can be quantified and thus does not account for nonquantifiable measures such as pain quality. Consequently, investigators who wish to assess certain aspects of the pain experience may prefer examinations that place greater emphasis on the nature of pain (i.e., SF-MPQ-2), while those who prefer integration of factors related to the anatomy, time course, and intensity of pain may prefer the IPQI. Also, the generalizability of IPQI results presented here may be limited to our study population of SCS-eligible chronic pain patients, the vast majority suffering from chronic musculoskeletal pain disorders. IPQI values were not saturated with the study population, with very few subjects in the 0-0.2 and 0.8-1 IPQI category. Still, though IPQI scores for this population may not be representative of other populations, the scale's use of variables common to all pain patients and our exclusion of patients already implanted with an SCS device suggest its applicability to all painful conditions, even in patients who are not SCS-eligible.
Finally, it should also be mentioned that we used a unidimensional index, which cannot capture all of the information within input variables. However, this loss of information comes with a corresponding gain in interpretability and ease of use.
